☰

Richard Honkanen - Publications

Affiliations: 
University of South Alabama, Mobile, AL, United States 
Area:
Biochemistry
Tree Info Similar researchers PubMed Report error

38 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Wu CG, Balakrishnan VK, Merrill RA, Parihar PS, Konovolov K, Chen YC, Xu Z, Wei H, Sundaresan R, Cui Q, Wadzinski BE, Swingle MR, Musiyenko A, Chung WK, Honkanen RE, et al. B56δ long-disordered arms form a dynamic PP2A regulation interface coupled with global allostery and Jordan's syndrome mutations. Proceedings of the National Academy of Sciences of the United States of America. 121: e2310727120. PMID 38150499 DOI: 10.1073/pnas.2310727120  0.712
2023 Smolen KA, Papke CM, Swingle MR, Musiyenko A, Li C, Salter EA, Camp AD, Honkanen RE, Kettenbach AN. Quantitative proteomics and phosphoproteomics of PP2A-PPP2R5D variants reveal deregulation of RPS6 phosphorylation via converging signaling cascades. The Journal of Biological Chemistry. 105154. PMID 37572851 DOI: 10.1016/j.jbc.2023.105154  0.724
2023 Salter EA, Wierzbicki A, Honkanen RE, Swingle MR. Quantum-based modeling implies that bidentate Arg-substrate binding enhances serine/threonine protein phosphatase-2A(PPP2R5D/PPP2R1A/PPP2CA)-mediated dephosphorylation. Frontiers in Cell and Developmental Biology. 11: 1141804. PMID 37377738 DOI: 10.3389/fcell.2023.1141804  0.708
2023 Wu CG, Balakrishnan VK, Parihar PS, Konovolov K, Chen YC, Merrill RA, Wei H, Carragher B, Sundaresan R, Cui Q, Wadzinski BE, Swingle MR, Musiyenko A, Honkanen R, Chung WK, et al. Extended regulation interface coupled to the allosteric network and disease mutations in the PP2A-B56δ holoenzyme. Biorxiv : the Preprint Server For Biology. PMID 37066309 DOI: 10.1101/2023.03.09.530109  0.7
2021 Shuhaibar LC, Kaci N, Egbert JR, Horville T, Loisay L, Vigone G, Uliasz TF, Dambroise E, Swingle MR, Honkanen RE, Biosse Duplan M, Jaffe LA, Legeai-Mallet L. Phosphatase inhibition by LB-100 enhances BMN-111 stimulation of bone growth. Jci Insight. 6. PMID 33986191 DOI: 10.1172/jci.insight.141426  0.688
2021 Papke CM, Smolen KA, Swingle MR, Cressey L, Heng RA, Toporsian M, Deng L, Hagen J, Shen Y, Chung WK, Kettenbach AN, Honkanen RE. A disorder-related variant (E420K) of a PP2A-regulatory subunit (PPP2R5D) causes constitutively active AKT-mTOR signaling and uncoordinated cell growth. The Journal of Biological Chemistry. 100313. PMID 33482199 DOI: 10.1016/j.jbc.2021.100313  0.678
2019 D'Arcy BM, Swingle MR, Schambeau L, Pannell L, Prakash A, Honkanen RE. Development of a Synthetic 3-ketosteroid Δ-dehydrogenase for the Generation of a Novel Catabolic Pathway Enabling Cholesterol Degradation in Human Cells. Scientific Reports. 9: 5969. PMID 30979909 DOI: 10.1038/S41598-019-42046-8  0.663
2019 D'Arcy BM, Swingle MR, Papke CM, Abney KA, Bouska ES, Prakash A, Honkanen RE. The Antitumor Drug LB-100 is a Catalytic Inhibitor of Protein Phosphatase 2A (PPP2CA) and 5 (PPP5C) Coordinating with the Catalytic Metals in the Active Site of PP5C. Molecular Cancer Therapeutics. PMID 30679389 DOI: 10.1158/1535-7163.Mct-17-1143  0.721
2018 Swingle MR, Honkanen RE. Inhibitors of Serine/Threonine Protein Phosphatases: Biochemical and Structural Studies Provide Insight for Further Development. Current Medicinal Chemistry. PMID 29737249 DOI: 10.2174/0929867325666180508095242  0.735
2017 Choy MS, Swingle M, D'Arcy B, Abney K, Rusin SF, Kettenbach AN, Page R, Honkanen RE, Peti W. The PP1:tautomycetin complex reveals a path towards the development of PP1-specific inhibitors. Journal of the American Chemical Society. PMID 29156132 DOI: 10.1021/Jacs.7B09368  0.727
2016 Swingle M, Volmar CH, Saldanha SA, Chase P, Eberhart C, Salter EA, D'Arcy B, Schroeder CE, Golden JE, Wierzbicki A, Hodder P, Honkanen RE. An Ultra-High-Throughput Screen for Catalytic Inhibitors of Serine/Threonine Protein Phosphatases Types 1 and 5 (PP1C and PP5C). Journal of Biomolecular Screening. PMID 27628691 DOI: 10.1177/1087057116668852  0.713
2016 Chattopadhyay D, Swingle MR, Salter EA, Wood E, D'Arcy B, Zivanov C, Abney K, Musiyenko A, Rusin SF, Kettenbach A, Yet L, Schroeder CE, Golden JE, Dunham WH, Gingras AC, ... ... Honkanen RE, et al. Crystal Structures and Mutagenesis of PPP-family ser/thr Protein Phosphatases Elucidate the Selectivity of Cantharidin and Novel Norcantharidin-based Inhibitors of PP5C. Biochemical Pharmacology. PMID 27002182 DOI: 10.1016/J.Bcp.2016.03.011  0.724
2014 Swingle MR, Honkanen RE. Development and validation of a robust and sensitive assay for the discovery of selective inhibitors for serine/threonine protein phosphatases PP1α (PPP1C) and PP5 (PPP5C). Assay and Drug Development Technologies. 12: 481-96. PMID 25383722 DOI: 10.1089/adt.2014.603  0.734
2014 Mazalouskas MD, Godoy-Ruiz R, Weber DJ, Zimmer DB, Honkanen RE, Wadzinski BE. Small G proteins Rac1 and Ras regulate serine/threonine protein phosphatase 5 (PP5)·extracellular signal-regulated kinase (ERK) complexes involved in the feedback regulation of Raf1. The Journal of Biological Chemistry. 289: 4219-32. PMID 24371145 DOI: 10.1074/Jbc.M113.518514  0.355
2014 Fransson L, Rosengren V, Saha TK, Grankvist N, Islam T, Honkanen RE, Sjöholm Å, Ortsäter H. Mitogen-activated protein kinases and protein phosphatase 5 mediate glucocorticoid-induced cytotoxicity in pancreatic islets and β-cells. Molecular and Cellular Endocrinology. 383: 126-36. PMID 24361515 DOI: 10.1016/j.mce.2013.12.010  0.301
2011 Amable L, Grankvist N, Largen JW, Ortsäter H, Sjöholm Å, Honkanen RE. Disruption of serine/threonine protein phosphatase 5 (PP5:PPP5c) in mice reveals a novel role for PP5 in the regulation of ultraviolet light-induced phosphorylation of serine/threonine protein kinase Chk1 (CHEK1). The Journal of Biological Chemistry. 286: 40413-22. PMID 21921034 DOI: 10.1074/jbc.M111.244053  0.343
2011 Yang X, Liu Y, Yang XM, Hu F, Cui L, Swingle MR, Honkanen RE, Soltani P, Tissier R, Cohen MV, Downey JM. Cardioprotection by mild hypothermia during ischemia involves preservation of ERK activity. Basic Research in Cardiology. 106: 421-30. PMID 21399968 DOI: 10.1007/s00395-011-0165-0  0.7
2010 Burke CP, Swingle MR, Honkanen RE, Boger DL. Total synthesis and evaluation of phostriecin and key structural analogues. The Journal of Organic Chemistry. 75: 7505-13. PMID 20669916 DOI: 10.1021/Jo1010203  0.71
2009 Swingle MR, Amable L, Lawhorn BG, Buck SB, Burke CP, Ratti P, Fischer KL, Boger DL, Honkanen RE. Structure-activity relationship studies of fostriecin, cytostatin, and key analogs, with PP1, PP2A, PP5, and( beta12-beta13)-chimeras (PP1/PP2A and PP5/PP2A), provide further insight into the inhibitory actions of fostriecin family inhibitors. The Journal of Pharmacology and Experimental Therapeutics. 331: 45-53. PMID 19592665 DOI: 10.1124/Jpet.109.155630  0.754
2008 Golden T, Aragon IV, Rutland B, Tucker JA, Shevde LA, Samant RS, Zhou G, Amable L, Skarra D, Honkanen RE. Elevated levels of Ser/Thr protein phosphatase 5 (PP5) in human breast cancer. Biochimica Et Biophysica Acta. 1782: 259-70. PMID 18280813 DOI: 10.1016/J.Bbadis.2008.01.004  0.504
2008 Golden T, Swingle M, Honkanen RE. The role of serine/threonine protein phosphatase type 5 (PP5) in the regulation of stress-induced signaling networks and cancer. Cancer Metastasis Reviews. 27: 169-78. PMID 18253812 DOI: 10.1007/S10555-008-9125-Z  0.707
2007 Ni L, Swingle MS, Bourgeois AC, Honkanen RE. High yield expression of serine/threonine protein phosphatase type 5, and a fluorescent assay suitable for use in the detection of catalytic inhibitors. Assay and Drug Development Technologies. 5: 645-53. PMID 17939754 DOI: 10.1089/Adt.2007.079  0.758
2007 Swingle M, Ni L, Honkanen RE. Small-molecule inhibitors of ser/thr protein phosphatases: specificity, use and common forms of abuse. Methods in Molecular Biology (Clifton, N.J.). 365: 23-38. PMID 17200551 DOI: 10.1385/1-59745-267-X:23  0.745
2007 Boger D, Lawhorn B, Boga S, Wolkenberg S, Colby D, Gauss C, Swingle M, Amable L, Honkanen R. Synthesis of Cytostatin Synfacts. 2007: 0456-0456. DOI: 10.1055/S-2007-968390  0.643
2006 Lawhorn BG, Boga SB, Wolkenberg SE, Colby DA, Gauss CM, Swingle MR, Amable L, Honkanen RE, Boger DL. Total synthesis and evaluation of cytostatin, its C10-C11 diastereomers, and additional key analogues: impact on PP2A inhibition. Journal of the American Chemical Society. 128: 16720-32. PMID 17177422 DOI: 10.1021/Ja066477D  0.681
2004 Golden T, Aragon IV, Zhou G, Cooper SR, Dean NM, Honkanen RE. Constitutive over expression of serine/threonine protein phosphatase 5 (PP5) augments estrogen-dependent tumor growth in mice. Cancer Letters. 215: 95-100. PMID 15374638 DOI: 10.1016/J.Canlet.2004.03.027  0.525
2004 Zhou G, Golden T, Aragon IV, Honkanen RE. Ser/Thr protein phosphatase 5 inactivates hypoxia-induced activation of an apoptosis signal-regulating kinase 1/MKK-4/JNK signaling cascade. The Journal of Biological Chemistry. 279: 46595-605. PMID 15328343 DOI: 10.1074/Jbc.M408320200  0.575
2004 Swingle MR, Honkanen RE, Ciszak EM. Structural basis for the catalytic activity of human serine/threonine protein phosphatase-5. The Journal of Biological Chemistry. 279: 33992-9. PMID 15155720 DOI: 10.1074/jbc.M402855200  0.714
2003 Buck SB, Hardouin C, Ichikawa S, Soenen DR, Gauss CM, Hwang I, Swingle MR, Bonness KM, Honkanen RE, Boger DL. Fundamental role of the fostriecin unsaturated lactone and implications for selective protein phosphatase inhibition. Journal of the American Chemical Society. 125: 15694-5. PMID 14677930 DOI: 10.1021/Ja038672N  0.724
2003 Honkanen RE, Golden T. Regulators of serine/threonine protein phosphatases at the dawn of a clinical era? Current Medicinal Chemistry. 9: 2055-75. PMID 12369870 DOI: 10.2174/0929867023368836  0.386
2001 Dean DA, Urban G, Aragon IV, Swingle M, Miller B, Rusconi S, Bueno M, Dean NM, Honkanen RE. Serine/threonine protein phosphatase 5 (PP5) participates in the regulation of glucocorticoid receptor nucleocytoplasmic shuttling. Bmc Cell Biology. 2: 6. PMID 11389770 DOI: 10.1186/1471-2121-2-6  0.695
2001 Sjöholm A, Berggren PO, Honkanen RE. Effects of second messengers on serine/threonine protein phosphatases in insulin-secreting cells. Biochemical and Biophysical Research Communications. 283: 364-8. PMID 11327709 DOI: 10.1006/bbrc.2001.4789  0.331
2000 Huang X, Swingle MR, Honkanen RE. Photoreceptor serine/threonine protein phosphatase type 7: cloning, expression, and functional analysis. Methods in Enzymology. 315: 579-93. PMID 10736728  0.686
2000 Sjöholm A, Honkanen RE. Polyamines regulate serine/threonine protein phosphatases in insulin-secreting cells. Pancreas. 20: 32-7. PMID 10630381 DOI: 10.1097/00006676-200001000-00005  0.347
1999 Connor JH, Kleeman T, Barik S, Honkanen RE, Shenolikar S. Importance of the beta12-beta13 loop in protein phosphatase-1 catalytic subunit for inhibition by toxins and mammalian protein inhibitors. The Journal of Biological Chemistry. 274: 22366-72. PMID 10428807 DOI: 10.1074/jbc.274.32.22366  0.319
1997 Walsh AH, Cheng A, Honkanen RE. Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A. Febs Letters. 416: 230-4. PMID 9373158 DOI: 10.1016/S0014-5793(97)01210-6  0.318
1994 Honkanen RE, Codispoti BA, Tse K, Boynton AL, Honkanan RE. Characterization of natural toxins with inhibitory activity against serine/threonine protein phosphatases. Toxicon : Official Journal of the International Society On Toxinology. 32: 339-50. PMID 8016855 DOI: 10.1016/0041-0101(94)90086-8  0.333
1993 Honkanen RE. Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A. Febs Letters. 330: 283-6. PMID 8397101 DOI: 10.1016/0014-5793(93)80889-3  0.342
Show low-probability matches.